With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
Donovan Quill, AscellaHealth’s Executive Vice President of Growth and Strategy, describes the unique challenges associated with bringing new specialty and rare disease pharmaceutical produc
Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners
The life sciences community is a powerful force determined to bring hope and healing to people around the world through relentless research and exploration.
At the upcoming World Without Disease Summit in London, many speakers will focus on specific treatments, therapies, and programmes that exemplify disease screening, prevention, and interception.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl